A self-expanding stent, manufactured by the French firm Stentys, has been proven to reduce the incidence of cardiac complications versus standard stents in circulation currently. The company now plans to expand into many new territories around the world, including the $3 billion United States market,
according to a Reuters report.
The
American College of Cardiology presented positive findings on the Stentys self-expanding stent at the ACC's
annual conference this weekend.
According to the study, which featured a universe of 1000 heart patients, the Stentys self-expanding mesh design produced negative cardiac events at a 9.3 percent rate compared to 11.1 percent from standard stents currently in use worldwide. Additional studies have found the self-expanding stent to yield a death rate of 2 percent versus 3.9 percent from traditional stents in market.
Citing a late 2011
analysis from Global Industry Analysts, Inc., the global stent market is projected to reach $9.8 billion by 2017.
Stentys hopes to receive approval from the U.S. Food and Drug Administration by 2015.
